This symposium aims to deliver the latest updates in benign hematology with a special emphasis on venous thromboembolism (VTE) and anticoagulation. The 2024 program will focus on three main areas:
- Current challenges in VTE
- Novel anticoagulants
- Thrombotic complications of clonal disorders
Key topics will include thrombophilia testing, the role of interventional radiology in VTE management, and challenging scenarios such as chronic thromboembolic pulmonary hypertension (CTEPH), refractory thrombosis, and splanchnic thrombosis.
Additionally, faculty will review the reversal of direct oral anticoagulants, novel factor XI inhibitors, and unique challenges in the management of thrombosis and clonal disorders (e.g., PNH, myeloproliferative neoplasm, and clonal hematopoiesis). Ample time will be allocated for Q&A and discussions with the faculty.
Objectives
- Provide guidance and updates on management of challenging thrombotic conditions including indications for thrombophilia testing, role of interventional radiology, management of refractory thrombosis, PNH, and anticoagulation in brain tumors.
- Summarize recent data on management of anticoagulant related hemorrhage and discuss emerging FXI inhibitors and their potential for improved safety profiles.
- Recognize the challenges in managing thrombo-hemorrhagic risks in patients with myeloproliferative neoplasms.
Target Audience and Format
The target audience includes general medicine practitioners, hematologists/oncologists, emergency medicine practitioners, primary care physicians, and other healthcare professionals involved in the management and treatment of thrombotic and bleeding disorders. Additionally, complimentary registration is available for patients, advocates, and caregivers to attend this program. More information here.
